The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment
S Rudin, M Marable, RS Huang - Genomics, Proteomics and …, 2017 - academic.oup.com
Pediatric acute lymphoblastic leukemia (ALL) affects a substantial number of children every
year and requires a long and rigorous course of chemotherapy treatments in three stages …
year and requires a long and rigorous course of chemotherapy treatments in three stages …
Use of allopurinol to mitigate 6-mercaptopurine associated gastrointestinal toxicity in acute lymphoblastic leukemia
SE Conneely, SL Cooper, RE Rau - Frontiers in Oncology, 2020 - frontiersin.org
An essential component of acute lymphoblastic leukemia (ALL) therapy is the prolonged
maintenance phase with daily 6-mercaptopurine (6-MP) as the cornerstone. While 6-MP is …
maintenance phase with daily 6-mercaptopurine (6-MP) as the cornerstone. While 6-MP is …
Allopurinol to prevent mercaptopurine adverse effects in children and young adults with acute lymphoblastic leukemia
R Kamojjala, B Bostrom - Journal of Pediatric Hematology …, 2021 - journals.lww.com
Mercaptopurine (6MP) is used to treat acute lymphoblastic leukemia (ALL) and is
metabolized by hypoxanthine guanine phosphoribosal transferase to form 6-thioguanine …
metabolized by hypoxanthine guanine phosphoribosal transferase to form 6-thioguanine …
Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6‐mercaptopurine metabolism, improving inadequate …
G Cohen, S Cooper, EA Sison… - Pediatric blood & …, 2020 - Wiley Online Library
Background Inadequate myelosuppression during maintenance therapy for acute
lymphoblastic leukemia (ALL) is associated with an increased risk of relapse. One …
lymphoblastic leukemia (ALL) is associated with an increased risk of relapse. One …
[HTML][HTML] 6-mercaptopurine promotes energetic failure in proliferating T cells
AA Fernández-Ramos, C Marchetti-Laurent… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Abstract The anticancer drug 6-mercaptopurine (6-MP) inhibits de novo purine synthesis
and acts as an antiproliferative agent by interfering with protein, DNA and RNA synthesis …
and acts as an antiproliferative agent by interfering with protein, DNA and RNA synthesis …
[HTML][HTML] Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment
C Wemyss, E Jones, R Stentz, SR Carding - Cancers, 2024 - pmc.ncbi.nlm.nih.gov
Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) remain significant
challenges in haematological oncology. This review examines the pathophysiology …
challenges in haematological oncology. This review examines the pathophysiology …
Cytostatic Drug 6-Mercaptopurine Degradation on Pilot Scale Reactors by Advanced Oxidation Processes: UV-C/H2O2 and UV-C/TiO2/H2O2 Kinetics
LA González-Burciaga, JC García-Prieto… - Catalysts, 2021 - mdpi.com
6-Mercaptopurine (6-MP) is a commonly used cytostatic agent, which represents a particular
hazard for the environment because of its low biodegradability. In order to degrade 6-MP …
hazard for the environment because of its low biodegradability. In order to degrade 6-MP …
A retrospective review of mercaptopurine metabolism reveals high rate of patients with suboptimal metabolites successfully corrected with allopurinol
LM Vasta, RC Zanetti, DS Parekh… - Journal of pediatric …, 2021 - journals.lww.com
Skewed drug metabolism of 6-mercaptopurine (6-MP) can jeopardize antileukemic effects
and result in toxicities during the treatment of acute lymphoblastic leukemia and …
and result in toxicities during the treatment of acute lymphoblastic leukemia and …
[HTML][HTML] Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia
M Zhang, B Bostrom - F1000Research, 2019 - ncbi.nlm.nih.gov
Fasting hypoglycemia is a known complication of mercaptopurine (6MP) maintenance
therapy for acute lymphoblastic leukemia (ALL). It is associated with high levels of the …
therapy for acute lymphoblastic leukemia (ALL). It is associated with high levels of the …
Prevention of mercaptopurine‐induced hypoglycemia using allopurinol to reduce methylated thiopurine metabolites
MB Miller, J Brackett, ES Schafer… - Pediatric Blood & …, 2019 - Wiley Online Library
Abstract Skewing of mercaptopurine (6‐MP) metabolism preferentially toward the 6‐
methylmercaptopurine (6‐MMP) metabolite over the antileukemic metabolite 6‐thioguanine …
methylmercaptopurine (6‐MMP) metabolite over the antileukemic metabolite 6‐thioguanine …